Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer

No abstract is available for this paper.

• Publication year

  2004

• Venue

  The Journal of Urology

• Publication date

  2004-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.JU.0000136430.37245.B9
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential alterations in 5α‐reductase type 1 and type 2 levels during development and progression of prostate cancer

  2005cited by this paper
• 1915: l8F-Flourodeoxyglucose Positron Emission Tomography (PET) Predicts for Metastatic Disease in Evaluation of Germ Cell Tumour Following Chemotherapy

  2004cited by this paper
• Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.

  2004cited by this paper
• Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.

  2004cited by this paper
• Dutasteride, the dual 5α–reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line

  2004cited by this paper
• Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.

  2004cited by this paper
• Does finasteride alter the pathology of the prostate and cancer grading?

  2004cited by this paper
• Quantitation of apoptotic activity following castration in human prostatic tissue in vivo

  2003cited by this paper
• The clinical implications of the Prostate Cancer Prevention Trial

  2003cited by this paper
• Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells.

  2003cited by this paper
• Decreased gene expression of steroid 5 alpha‐reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma

  2003cited by this paper
• 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.

  2003cited by this paper
• The influence of finasteride on the development of prostate cancer.

  2003cited by this paper
• Three‐month neoadjuvant hormonal therapy before radical prostatectomy: a 7‐year follow‐up of a randomized controlled trial

  2002cited by this paper
• Inhibition of vascular endothelial growth factor in the treatment of solid tumors

  2002cited by this paper
• Prostatic intraepithelial neoplasia and putative precursor lesions of prostate cancer: a clinical perspective

  2001cited by this paper
• Androgen blocks apoptosis of hormone-dependent prostate cancer cells.

  2001cited by this paper
• Similarities of prostate and breast cancer: Evolution, diet, and estrogens.

  2001cited by this paper
• Re: Chemoprevention of urological cancer.

  2000cited by this paper
• Re: Back to future-the role of complementary medicine in urology.

  2000cited by this paper
• Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation

  1999cited by this paper
• The utility of tissue transglutaminase as a marker of apoptosis during treatment and progression of prostate cancer.

  1999cited by this paper
• Differences in steroid 5α-reductase iso-enzymes expression between normal and pathological human prostate tissue

  1999cited by this paper
• Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.

  1999cited by this paper
• Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice.

  1998cited by this paper
• Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

  1998cited by this paper
• Differential expression of 5α‐reductase isoenzymes in the human prostate and prostatic carcinomas

  1996cited by this paper
• Evidence for atrophy and apoptosis in the prostates of men given finasteride.

  1996cited by this paper
• Histopathological effects of androgen deprivation in prostatic cancer.

  1996cited by this paper
• Urologic causes of gynecomastia: approach to diagnosis and management.

  1995cited by this paper
• Expression and regulation of steroid 5α-reductase 2 in prostate disease

  1994cited by this paper
• Response of rat and human prostatic cancers to the novel 5α‐reductase inhibitor, SK&F 105657

  1992cited by this paper
• Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.

  1992cited by this paper
• Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency.

  1992cited by this paper
• 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males.

  1992cited by this paper
• Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.

  1990cited by this paper
• Interaction between prostatic fibroblast and epithelial cells in culture: role of androgen.

  1989cited by this paper
• Kinetic parameters of 5 alpha-reductase activity in stroma and epithelium of normal, hyperplastic, and carcinomatous human prostates.

  1988cited by this paper
• The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications

  1986cited by this paper

• A concise review- Development of an analytical method and validation of dutasteride

  2025cites this paper
• PROSTATE AS A TARGET OF ENDOCRINE DISRUPTING CHEMICALS: RELEVANCE, PATHWAYS, ASSAYS.

  2025cites this paper
• Subchronic intake of arsenic at environmentally relevant concentrations causes histological lesions and oxidative stress in the prostate of adult Wistar rats.

  2024cites this paper
• Largo trabajo y mucho que resolver aún sobre las isoenzimas de la 5-alfa reductasa Revisión bibliográfica

  2024cites this paper
• In vitro 5α-reductase inhibition by selected Ayurvedic herbs for androgenic disorders

  2024cites this paper
• Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratification Scoring System

  2024cites this paper
• Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment

  2021cites this paper
• Five-alpha reductase inhibitors in men undergoing active surveillance for prostate cancer: impact on treatment and reclassification after 6 years follow-up

  2021cites this paper
• Nonneoplastic Diseases of the Prostate

  2020cites this paper
• Neoplasms of the Prostate

  2020cites this paper
• A numerical simulation study of the dual role of5α-reductase inhibitors on tumor growth in prostates enlarged by benign prostatic hyperplasia via stress relaxation and apoptosis upregulation

  2020cites this paper
• ARe we there yet? Understanding androgen receptor signaling in breast cancer

  2020cites this paper
• Azasteroids from diosgenin: Synthesis and evaluation of their antiproliferative activity.

  2020cites this paper
• The effects of Pueraria mirifica extract, diadzein and genistein in testosterone-induced prostate hyperplasia in male Sprague Dawley rats

  2019cites this paper
• Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting

  2019cites this paper
• Discovery and Development of Azasteroids as Anticancer Agents.

  2019cites this paper
• Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR).

  2019cites this paper
• Prostate Cancer Histopathology Reporting Guide Transurethral Resection and Enucleation

  2018cites this paper
• Computer vision detects subtle histological effects of dutasteride on benign prostate

  2018cites this paper
• Dehydroepiandrosterone (DHEA)-SO4 Depot and Castration-Resistant Prostate Cancer.

  2018influential citation
• Change of the 5α/5β ratio of urinary steroid metabolites in benign prostatic hyperplasia patients treated with dutasteride.

  2018cites this paper
• Pre-Androgen Ablation Prostate Cancer Patients Who Bleed Do Well with 5 Alpha Reductase Inhibitors

  2018cites this paper
• Identification of signalling pathways involved in the oxidative stress response triggered by Low Temperature Plasma in prostate epithelial cells and the assessment of tumour-associated allelic expression in prostate cancer

  2018cites this paper
• The Role of Dutasteride in Acute Prostatic Haematuria

  2017cites this paper
• Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy

  2017cites this paper
• Prognostic influence of 5 alpha reductase inhibitors in patients with localized prostate cancer under active surveillance.

  2017cites this paper
• Early dutasteride monotherapy in men with detectable serum prostate-specific antigen levels following radical prostatectomy: A prospective trial

  2017cites this paper
• Targeting phenotypic heterogeneity in benign prostatic hyperplasia.

  2017cites this paper
• New insights in steroid hormone metabolism in prostate cancer

  2017cites this paper
• The impact of finasteride and dutasteride treatments on proliferation, apoptosis, androgen receptor, 5α-reductase 1 and 5α-reductase 2 in TRAMP mouse prostates

  2017cites this paper
• Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume

  2017cites this paper
• Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.

  2017cites this paper
• Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial)

  2017cites this paper
• THE ROLE OF 5-ALPHA REDUCTASE 3 IN STEROID METABOLISM

  2016cites this paper
• A Systematic Review and Meta-Analysis of the Effects on Dutasteride Treatment for Reducing Surgical Blood Loss during Transurethral Resection of the Prostate

  2016cites this paper
• Design and Synthesis of Novel Azasteroids and Pseudoazulenyl Nitrones

  2016influential citation
• Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer☆

  2016cites this paper
• Is There a Future for Chemoprevention of Prostate Cancer?

  2016cites this paper
• Application of transrectal ultrasound-guided repeat needle biopsy in the diagnosis of prostate cancer in Chinese population: A retrospective study

  2016cites this paper
• THE ROLE OF 5-ALPHA REDUCTASE 3 IN STEROID METABOLISM

  2016cites this paper
• A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia

  2015cites this paper
• Risk of Fractures and Falls during and after 5-α Reductase Inhibitor Use: A Nationwide Cohort Study

  2015cites this paper
• ADual 5αα-Reductase Inhibitor Dutasteride Caused Reductions in Vascular Density and Area in Benign Prostatic Hyperplasia

  2015cites this paper
• Histologic evaluation of human benign prostatic hyperplasia treated by dutasteride: a study by xenograft model with improved severe combined immunodeficient mice.

  2015cites this paper
• Detection of hepatitis B virus DNA in serum is rare in the absence of hepatitis B surface antigen: impacts for detection and monitoring of chronic hepatitis B.

  2014cites this paper
• 5-Alpha reductase inhibitors and PSA screening for prostate cancer.

  2014cites this paper
• 5α‐reductase type 3 enzyme in benign and malignant prostate

  2014cites this paper
• Effect of dutasteride on microvessel density in benign prostatic hyperplasia.

  2014cites this paper
• Controlled Release of Dutasteride from Biodegradable Microspheres: In Vitro and In Vivo Studies

  2014cites this paper
• 5ARI and PSA: open questions

  2014cites this paper
• 5-Alpha reductase inhibitors in active surveillance

  2014cites this paper
• Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α‐reductase inhibitors

  2013cites this paper
• Prostate Cancer Detection: Lessons Learned in the Cleveland Clinic Experience with Focus on the Negative Biopsy

  2013cites this paper
• Hair loss and herbs for treatment

  2013cites this paper
• A Dual 5α-Reductase Inhibitor Dutasteride Caused Reductions in Vascular Density and Area in Benign Prostatic Hyperplasia

  2013cites this paper
• Development of a new gas chromatography-mass spectrometry (GC-MS) methodology for the evaluation of 5α-reductase activity.

  2013cites this paper
• Androgens and prostate disease

  2013cites this paper
• Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer

  2012cites this paper
• Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum

  2012cites this paper
• Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial

  2012cites this paper
• Dutasteride, who is it more effective for? Second to fourth digit ratio and the relationship with prostate volume reduction by dutasteride treatment

  2012cites this paper
• Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.

  2012cites this paper
• Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer

  2012cites this paper
• Review Article Role of 5-Reductase Inhibitors in Prostate Cancer Prevention and Treatment

  2012cites this paper
• Personalized Cancer Therapy for Urological Cancers: From Bench to Bedside and Back

  2012influential citation
• Usefulness of prostate‐specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study

  2012cites this paper
• Overcoming castration resistance in prostate cancer

  2012cites this paper
• Role of 5 a-reductase inhibitors in benign prostatic diseases

  2012cites this paper
• Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: a pilot study.

  2012cites this paper
• Effect of Discontinuation of Tamsulosin in Korean Men with Benign Prostatic Hyperplasia Taking Tamsulosin and Dutasteride: An Open‐Label, Prospective, Randomized Pilot Study

  2012cites this paper
• The Effect of Finasteride and Dutasteride on the Growth of WPE1-NA22 Prostate Cancer Xenografts in Nude Mice

  2012cites this paper
• Dutasteride

  2012cites this paper
• Transurethral resection of the prostate : how to reduce morbidity

  2011cites this paper
• Prostate cancer detection after a negative prostate biopsy: Lessons learnt in the Cleveland Clinic experience

  2011cites this paper
• THE EFFECT OF FINASTERIDE AND DUTASTERIDE ON THE GROWTH OF WPE1- NA22 PROSTATE CANCER XENOGRAFTS IN NUDE MICE by ALEXANDER

  2011cites this paper
• Targeting 5α-reductase for prostate cancer prevention and treatment

  2011cites this paper
• The use of 5α-reductase inhibitors for the prevention and treatment of prostate cancer.

  2011cites this paper
• The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride

  2010cites this paper
• Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial.

  2010cites this paper
• The Mechanism of Androgen Deprivation and the Androgen Receptor

  2010cites this paper
• Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer.

  2010cites this paper
• Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention.

  2010cites this paper
• Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.

  2010cites this paper
• New developments in the medical management of prostate cancer.

  2010cites this paper
• Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α‐reductase

  2009cites this paper
• Effect of Steroid 5α-Reductase Inhibitors on Markers of Tumor Regression and Proliferation in Prostate Cancer

  2009cites this paper
• Novel secondary hormonal therapy in advanced prostate cancer: an update

  2009cites this paper
• Capítulo 78 – Cáncer de próstata

  2009cites this paper
• Overview of pivotal studies for prostate cancer risk reduction, past and present.

  2009cites this paper
• Molecular Profiles of Finasteride Effects on Prostate Carcinogenesis

  2009cites this paper
• Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer.

  2009cites this paper
• Therapie des benignen Prostatasyndroms (BPS)

  2009cites this paper
• Emerging drugs for prostate cancer

  2009cites this paper
• A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits

  2009cites this paper
• Effect of dutasteride on the expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and microvessel density in rat and human prostate tissue

  2009cites this paper
• Testosterone replacement in prostate cancer survivors with hypogonadal symptoms

  2009cites this paper
• Adjuvant androgen deprivation therapy loses its therapeutic benefit after premature termination: an experience of combined modality treatment on prostate cancer.

  2009cites this paper
• Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study

  2009cites this paper
• The Prostate 69 : 595 ^ 602 ( 2009 ) Overexpressionof 5 a-ReductaseType 1 Increases Sensitivityof ProstateCancerCells to Low Concentrations of Testosterone

  2009cites this paper
• Preliminary evaluation of the effect of dutasteride on PCA3 in post‐DRE urine sediments: A randomized, open‐label, parallel‐group pilot study

  2009cites this paper